Clinical Trial Update: A Prospective, Epidemiological Study to Assess the Disease Burden of Respiratory Syncytial Virus Associated, Suspected Lower Respiratory Tract Infections in Newborns, From 0 to 2 Years of Age and Risk of Development of Wheeze and Asthma From 0 to 6 Years of Age [NA]

View source ↗

Summary

Prospective epidemiological study assessing RSV disease burden in newborns and risk of wheeze/asthma up to age 6.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma
• Respiratory Syncytial Virus Disease
• Wheeze

Drugs mentioned

• GlaxoSmithKline

Snippet

Sponsor: GlaxoSmithKline | Conditions: Respiratory Syncytial Virus | NA | Status: COMPLETED | Results posted: 2019-02-15